NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced its participation in the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Biennial Meeting, taking place May 30-June 2, 2026, at the Hilton Cleveland Downtown. The company will present its recently 510(k)-cleared OneRF® Trigeminal Nerve Ablation System, designed to create radiofrequency lesions for treating chronic facial pain and for functional neurosurgical procedures. This system features a multi-contact RF probe that enables precise mapping and ablation in fewer cycles without repositioning, potentially reducing procedural time and improving patient comfort.
NeuroOne has completed the limited market release of the OneRF Trigeminal Nerve Ablation System. The system is indicated for use in procedures to create radiofrequency lesions for the treatment of pain or for lesioning nerve tissue for functional neurosurgical procedures, having received FDA 510(k) clearance under K251243.
Additionally, the company will share details on its SEEG-Drug Delivery System*, a device under development for investigational studies in humans and research in laboratory animals. The system is designed to deliver drugs, record neural activity, and stimulate, supporting multiple trajectories and enabling repeated dosing through a single implant. This platform aims to integrate drug delivery capabilities into a SEEG-based recording, stimulation, and ablation platform.
NeuroOne will present a scientific session titled "Integrating Drug Delivery Capabilities into a SEEG-Based Recording, Stimulation, and Ablation Platform Technology" on Sunday, May 31, 2026. The company will also present posters on SEEG-guided radiofrequency ablation with real-time temperature control and a new FDA-cleared multi-contact RF probe for trigeminal neuralgia.
Multiple neurosurgeon presentations will highlight clinical experiences with both the OneRF Radiofrequency Ablation System (for brain) and the OneRF Trigeminal Nerve Ablation System. The OneRF Radiofrequency Ablation System received FDA clearance under K231675.
NeuroOne markets a minimally invasive electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF Ablation System (for brain), and OneRF Trigeminal Nerve Ablation System. These solutions aim to reduce hospitalizations, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. The company is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs.
For more information, visit nmtc1.com.
*Caution: Device and tools for use in investigational studies in humans and for research in laboratory animals. Device and tools are under development and not approved/cleared by FDA or any Regulatory Agency for sale.
